Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | ADH5 | P11766 | 10/20 | 0.60 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488338 | 1.00 | IDO1 (0.61) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL3118463 | 0.87 | IDO1 (0.61) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL10758443 | 0.86 | CYP4Z1 (0.51) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL7280094 | 0.86 | CYP3A4 (0.67) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| Hydrochloric Acid SCHEMBL5869171 | 0.84 | IDO1 (0.62) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL5868816 | 0.84 | IDO1 (0.54) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL28424338 | 0.83 | ADH5 (0.63) | IDO1ADH5CYP4Z1CYP3A4BAZ2B | |
| SCHEMBL21652707 | 0.83 | ADH5 (0.63) | IDO1ADH5CYP4Z1CYP3A4BAZ2B | |
| SCHEMBL10663235 | 0.83 | IDO1 (0.52) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL17773158 | 0.82 | IDO1 (0.55) | IDO1ADH5CYP4Z1CYP3A4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | THE PENN STATE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-6323227-B1 | PRODRUGS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029011-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| US-6140504-A | Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6080767-A | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-27 | — | — | US | disclosed |
| US-5514693-A | THROMBOXANE A2 SYNTHETASE INHIBITOR, CALCIUM ANTAGONIST | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-05-07 | — | — | US | disclosed |
| EP-0373645-B1 | Imidazolyl and pyridyl derivatives of phenyl substituted 1,4 -dihyropyridines and process for their preparation | PHARMACIA SPA (IT) | 1995-04-19 | — | — | EP | disclosed |
| WO-1990006923-A1 | IMIDAZOLYL AND PYRIDYL DERIVATIVES OF PHENYL SUBSTITUTED 1,4-DIHYDRO-PYRIDINES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-06-28 | — | — | WO | disclosed |
| EP-0373645-A1 | Imidazolyl and pyridyl derivatives of phenyl substituted 1,4 -dihyropyridines and process for their preparation | PHARMACIA S.p.A. (IT) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | IDO1 938/4885ADH5 1092/4885CYP4Z1 250/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | IDO1 938/4885ADH5 1092/4885CYP4Z1 250/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | IDO1 1745/4885ADH5 129/4885CYP4Z1 2638/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | IDO1 3561/4885ADH5 3652/4885CYP4Z1 4248/4885 |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | CYP3A4, CYP4B1, CYP2C9 | IDO1 3577/4885ADH5 458/4885CYP4Z1 88/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | IDO1 1745/4885ADH5 129/4885CYP4Z1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.